<DOC>
	<DOCNO>NCT02484638</DOCNO>
	<brief_summary>The purpose study investigate pharmacokinetics ( PK ) , efficacy , safety rVIIa-FP ( CSL689 ) . The study enroll total 54 male subject , 12 65 year age , hemophilia type A B develop inhibitor FVIII FIX . The study consist 3 sequential part ( Parts 1 , 2 , 3 ) : The purpose Part 1 ( PK part ) evaluate PK single treatment CSL689 ( low dose high dose ) compare PK single treatment Eptacog alfa ( low dose high dose ) . In Part 1 , CSL689 Eptacog alfa give doctor study center . The purpose Part 2 ( Dose-evaluation part ) identify 2 test dose level CSL689 show best efficacy safety stop acute bleed event ( dose call `` population best dose '' ) . The purpose final Part 3 ( Repeated-dose part ) confirm efficacy safety `` population best dose '' identify Part 2 . In Parts 2 3 , subject self-administer specified number CSL689 infusion home on-demand ( ie , bleed event occurs ) , keep electronic diary , visit center monthly interval . This study expect last 16 month subject participate 3 part , 9 month subject participate Part 3 .</brief_summary>
	<brief_title>Study Recombinant Factor VIIa Fusion Protein ( rVIIa-FP , CSL689 ) On-demand Treatment Bleeding Episodes Patients With Hemophilia A B With Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Male subject hemophilia A B inhibitor . Age ≥ 12 ≤ 65 year . High respond inhibitor document historical inhibitor titer &gt; 5 Bethesda Units/mL . Congenital acquire coagulation disorder hemophilia A B . Ongoing immune tolerance induction therapy plan study . Known suspect hypersensitivity activate recombinant human FVII excipient CSL689 . Body mass index &gt; 30 kg/m² . Major surgery within 28 day screen scheduled major / orthopedic surgery study . Advanced atherosclerotic disease ( ie , known history ischemic heart disease , ischemic stroke ) . Any clinical sign know history thromboembolic event , include know deep vein thrombosis . Human immunodeficiency virus ( HIV ) positive subject low cluster differentiation 4 ( CD4 ) + lymphocyte count ( 200/μL less ) screening . Use follow within screen period plan study : ) plasma coagulation factor concentrate rescue therapy therapy Part 1 , b ) platelet inhibitor , c ) desmopressin , ) fibrinolysis inhibitor , except use local treatment ( eg , oral bleeds ) .</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>